Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study

The Saudi Food and Drug Authority (SFDA) approved sodium-glucose cotransporter-2 (SGLT2) inhibitors in 2018. The efficacy and safety of empagliflozin (EMPA) have been confirmed in the U.S., Europe, and Japan for patients with type 2 diabetes mellitus (T2DM); however, analogous evidence is lacking fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Althobaiti, Fahad M., Alsanosi, Safaa M., Falemban, Alaa H., Alzahrani, Abdullah R., Fataha, Salma A., Salih, Sara O., Alrumaih, Ali M., Alotaibi, Khalid N., Althobaiti, Hazim M., Al-Ghamdi, Saeed S., Ayoub, Nahla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410062/
https://www.ncbi.nlm.nih.gov/pubmed/36013008
http://dx.doi.org/10.3390/jcm11164769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410062/
https://www.ncbi.nlm.nih.gov/pubmed/36013008
http://dx.doi.org/10.3390/jcm11164769

Ejemplares similares